Mymetics Corporation (MYMX)
Mymetics Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Epalinges, VD, CH. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $46. On trailing twelve-month figures it carries a trailing P/E of -0.02, a net margin of -160166.7%. Its beta of 2.34 implies it has historically moved more than the broad market.
Mymetics Corporation is a Swiss biotechnology company dedicated to the research and development of vaccines aimed at preventing infectious and debilitating diseases. Its robust pipeline features several promising vaccine candidates, including those for HIV-1/AIDS, COVID-19, intranasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya. The company actively collaborates with leading institutions such as the Texas Biomedical Research Institute, the PATH Malaria Vaccine Initiative, and the National Institute of Allergy and Infectious Diseases' Laboratory of Malaria Immunology and Vaccinology, focusing on the development and production of virosome-based vaccine formulations for a malaria transmission-blocking agent. Additionally, Mymetics works with Sanofi Pasteur Biologics, LLC to assess the immunogenicity of influenza vaccines. Founded in 1990, the company was formerly known as ICHOR Corporation, adopting its current name in July 2001, and maintains its base of operations in Epalinges, Switzerland.
Mymetics Corporation is most often compared with the following Healthcare names: